ReviewInternational urology and nephrology2008
Inhibition of the renin-angiotensin system and chronic kidney disease.
Review in International urology and nephrology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial.International urology and nephrology · 2012Trial
- Cardiovascular and Renal Outcomes Following Repeated Naringenin Exposure in Normotensive and Hypertensive Rats.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Sodium glucose transporter 2 inhibitors: Will these drugs benefit non-diabetic veterinary patients with cardiac and kidney diseases?Journal of veterinary pharmacology and therapeutics · 2025Review
- The Footprints of Mitochondrial Fission and Apoptosis in Fluoride-Induced Renal Dysfunction.Biological trace element research · 2024Article
- Preventing the progression of chronic kidney disease: two case reports and review of the literature.International urology and nephrology · 2014Review
- Absolute quantification of endogenous angiotensin II levels in human plasma using ESI-LC-MS/MS.Clinical proteomics · 2014Article
- Improvement and influencing factors of blood pressure control by nephrologist referral in chronic kidney disease patients in China: a cohort study.International urology and nephrology · 2013Article
- Proteinuria in systemic sclerosis: reversal by ACE inhibition.Rheumatology international · 2013Article
- Feline CKD: New horizons - where do we go from here?Journal of feline medicine and surgery · 2013Review
- Potential of RAS inhibition to improve metabolic bone disorders.BioMed research international · 2013Review
- Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes.Patient related outcome measures · 2011Article
- Renal involvement in nail-patella syndrome: report of three cases.International urology and nephrology · 2010Article
- Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.International urology and nephrology · 2009Review
- Direct renin inhibitors: ONTARGET for success?International urology and nephrology · 2009Review
- Aliskiren: a rapidly, expanding role in the management of recalcitrant hypertension and renal disease.International urology and nephrology · 2008Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD), a major worldwide public-health problem which affects about 10% of the population, has an increased annual incidence rate of about 5-8%. This increased incidence is mainly due to type 2 diabetes and hypertension and the increasing incidence of elderly patients with CKD. Although the progression to end-stage renal failure (ESRF) is mainly based upon the underlying disease, comorbid conditions such as an initial low renal function, severe proteinuria, and high levels of blood pressure also play important roles in the development of ESRF. Since experimental and clinical evidence suggest that angiotensin II plays a central role in the progression of CKD, pharmacological inhibition of the renin-angiotensin-aldosteron system (RAAS) with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists has been suggested as first-line treatment for hypertension and prevention of ESRF in these patients. Aliskiren, a novel renin inhibitor is also a promising medical intervention. However, independently of the category of the drugs used, low target blood pressure levels seem to be equally or more important for the delay or prevention of CKD. In this review the results of studies with pharmacological inhibition of the RAAS in patients with diabetic and nondiabetic nephropathy is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.